分享好友 环球市场首页 环球市场分类 切换频道

U.S. Pharmaceutical Packaging Services Market (2025 - 2030)

2025-01-2000

Market Size & Trends

The U.S. pharmaceutical packaging services market size was estimated at USD 2.82 billion in 2024 and is expected to expand at a CAGR of 9.0% from 2025 to 2030. The market is experiencing substantial growth, primarily driven by the expansion of the country's pharmaceutical sector. In addition, an increasing shift towards serialization and anti-counterfeit measures is propelling the U.S. pharmaceutical packaging services industry growth in the country.

A key driver within the pharmaceutical industry is the biopharmaceutical segment, which focuses on biologics such as vaccines, monoclonal antibodies, and gene therapies. Biopharmaceuticals require specialized packaging solutions, including temperature-controlled and tamper-evident packaging, to maintain efficacy and safety. For instance, the COVID-19 pandemic spurred massive investments in cold-chain packaging for vaccines. Companies such as Pfizer and Moderna partnered with packaging firms to develop innovative solutions for their mRNA vaccines, demonstrating how the industry's growth stimulates the packaging sector.

In addition, as per the European Federation of Pharmaceutical Industries and Associations (EFPIA), the U.S. holds a significant position in the global production and sales of pharmaceuticals as well as carries out research activities to launch new pharmaceuticals in the market. The EFPIA data also states that the U.S. held a share of 64.4% of the global sales of new medicines launched from 2017 to 2022. As per the data provided by Pharmaceutical Research and Manufacturers of America (PhRMA), the research & development expenditure related to pharmaceuticals has witnessed an upward trend in the country from approximately USD 72,412.1 million in 2020 to approximately USD 79,610.2 million in 2021. Thus, this outlook is anticipated to exhibit a positive impact on the pharmaceutical packaging market growth in the U.S.

Moreover, an increasing emphasis on serialization and anti-counterfeit measures is a significant driver in the U.S. pharmaceutical packaging services industry. With the rising threats of counterfeit drugs entering the supply chain, regulatory mandates such as the Drug Supply Chain Security Act (DSCSA) require enhanced tracking, traceability, and authentication of pharmaceutical products. Serialization, which involves assigning unique identifiers to each package, is central to ensuring the integrity of the pharmaceutical supply chain. This trend has compelled packaging service providers to adopt advanced technologies and systems, transforming the industry landscape.

Product Insights

The branded product segment recorded the largest market revenue share of over 27.0% in 2024. The growth of branded pharmaceutical packaging services is driven by increased R&D investment in novel drugs, growing demand for premium healthcare products, and the need to combat counterfeit drugs. In addition, regulatory mandates on product traceability and safety enhance the demand for high-end packaging solutions.

Biosimilar packaging services involve packaging biologically derived products similar to already approved reference biologics. The increasing adoption of biosimilars due to their cost-effectiveness compared to biologics, coupled with the growing prevalence of chronic diseases such as cancer and autoimmune disorders, is driving the biosimilar packaging segment. Regulatory approvals and the growing pipeline of biosimilar drugs also contribute to the U.S. pharmaceutical packaging services industry growth.

Service Line Insights

The primary packaging segment accounted for the largest market share, over 43.0%, in 2024. Primary packaging refers to the packaging that comes into direct contact with the pharmaceutical product, and it is designed to protect the product from contamination, ensure dosage accuracy, and maintain stability. Primary packaging plays a crucial role in maintaining the sterility and efficacy of the drug. The growth of primary packaging is driven by the increasing demand for injectable drugs, biologics, and personalized medicines.

Secondary packaging involves packaging layers outside the primary packaging, such as cartons, boxes, and labels. It provides additional protection during storage and transportation and often contains vital product information, including batch numbers and expiry dates, to aid in product identification and compliance. Increasing focus on anti-counterfeiting measures, such as tamper-evident seals and advanced labeling technologies, is supporting the segment growth in the market.

Manufacturer Size Insights

The small manufacturer size segment recorded the largest market share of over 58.0% in 2024. This positive outlook can be attributed to the rise of contract packaging organizations (CPOs) and the outsourcing of non-core activities by smaller pharmaceutical firms. Furthermore, their ability to provide cost-effective, region-specific solutions in compliance with local regulations makes them highly competitive, thus driving segment growth in the U.S. pharmaceutical packaging services industry.

The medium manufacturer size segment in the market refers to companies that typically have a moderate scale of operations, serving a diverse range of pharmaceutical companies. Medium-sized pharmaceutical packaging service providers are distinguished by their ability to offer tailored packaging solutions. These manufacturers, typically more agile than their larger counterparts, can quickly adapt to shifting market demands or specific client needs. They provide a comprehensive range of packaging services, including primary, secondary, and tertiary packaging, all crucial for ensuring the protection, presentation, and secure transportation of pharmaceutical products.

Moreover, large manufacturers represent the most sophisticated and comprehensive players in the market. These companies typically have extensive infrastructure, advanced technological capabilities, and the financial resources to handle large-scale pharmaceutical packaging projects for major pharmaceutical companies, biotechnology firms, and global healthcare organizations. Their operations are characterized by state-of-the-art manufacturing facilities that meet the most stringent regulatory requirements, including FDA standards and international quality certifications such as ISO 15378.

Key U.S. Pharmaceutical Packaging Services Company Insights

The U.S. pharmaceutical packaging services market is highly competitive, driven by stringent regulatory requirements, rising demand for advanced drug delivery systems, and increasing emphasis on patient safety and product integrity. Key players such as SGS North America Inc., Intertek Group plc, and West Pharmaceutical Services, Inc. dominate the landscape, leveraging cutting-edge technology, extensive manufacturing capabilities, and comprehensive service offerings, including design, primary, secondary, and tertiary packaging. In addition, companies differentiate through value-added services such as regulatory compliance support, digital serialization, and end-to-end supply chain solutions, fostering strong partnerships with pharmaceutical manufacturers and driving market growth.

Key U.S. Pharmaceutical Packaging Services Companies:

  • SGS North America Inc.
  • All Packaging Services, LLC.
  • Intertek Group plc
  • PakFactory
  • Crown Packaging Corp.
  • U.S. Continental Packaging
  • Sharp Services, LLC
  • PCI Pharma Services
  • Aphena Pharma Solutions
  • Legacy Pharma Solutions
  • Wasdell Packaging Group
  • West Pharmaceutical Services, Inc.

U.S. Pharmaceutical Packaging Services Market